Analysts Set Expectations for MNPR FY2025 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Monopar Therapeutics in a research report issued on Monday, July 7th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings per share of ($1.30) for the year. Cantor Fitzgerald has a "Overweight" rating and a $74.00 price objective on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. Cantor Fitzgerald also issued estimates for Monopar Therapeutics' FY2026 earnings at ($3.09) EPS.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.27.

Several other equities analysts have also weighed in on MNPR. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. Piper Sandler reaffirmed an "overweight" rating and set a $76.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. Chardan Capital began coverage on shares of Monopar Therapeutics in a report on Monday, June 23rd. They issued a "buy" rating and a $60.00 price objective on the stock. Finally, Jones Trading reiterated a "hold" rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, Monopar Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $60.00.

Monopar Therapeutics Stock Performance

Shares of Monopar Therapeutics stock opened at $38.37 on Wednesday. The business's 50 day moving average price is $35.84 and its 200 day moving average price is $35.28. The company has a market cap of $234.82 million, a price-to-earnings ratio of -11.03 and a beta of 1.01. Monopar Therapeutics has a one year low of $1.72 and a one year high of $54.30.

Hedge Funds Weigh In On Monopar Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AlphaQuest LLC acquired a new stake in Monopar Therapeutics in the 1st quarter valued at about $44,000. JPMorgan Chase & Co. acquired a new stake in shares of Monopar Therapeutics during the fourth quarter worth about $45,000. Gerber LLC purchased a new stake in shares of Monopar Therapeutics in the 1st quarter valued at about $204,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Monopar Therapeutics in the 1st quarter valued at about $328,000. Finally, Jane Street Group LLC purchased a new position in Monopar Therapeutics during the 1st quarter worth approximately $377,000. Hedge funds and other institutional investors own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.